view low-bandwidth site

Lead Product: The EOSCAPE-HIV

Frequent measurement of the quantity of HIV RNA in peripheral blood—or viral load—is a crucial element of clinical decisionmaking in HIV patient care. The EOSCAPE HIV-1 RNA Test, or EOSCAPE-HIV, is a new tool for HIV-1 viral load testing with a unique combination of high performance, robust operation, and compact instrumentation. The EOSCAPE-HIV offers significant advantages compared to traditional nucleic acid testing systems in terms of reduced clinical laboratory infrastructure requirements, faster turnaround time, and streamlined sample acquisition/processing.

The EOSCAPE-HIV is a cartridge-format in vitro nucleic acid assay for the rapid detection and quantitation of human immunodeficiency virus type 1 (HIV-1) RNA. Using 100 microliter whole blood or plasma samples, typically from a fingerstick or a heelstick, the EOSCAPE-HIV quantitates HIV RNA with sample in-results out time of less than 50 minutes. Results are displayed on the integrated 18 cm touchscreen display and over a variety of electronic communications protocols, including HL7, SMS, and an optional attached printer.

The groundbreaking EOSCAPE system is a robust, fully automated cartridge-format system for high-clinical-value molecular diagnostic tests.

Figure 1: The groundbreaking EOSCAPE system is a robust, fully automated cartridge-format system for high-clinical-value molecular diagnostic tests. The lead assay, for quantitative HIV RNA testing for monitoring antiretroviral therapy, is scheduled for launch into select geographic markets in 2013.